A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer
Background The efficacy of weekly paclitaxel has not been well characterized in either cervical or endometrial cancer. Methods Eligible women had disseminated endometrial or squamous cell cancer of the cervix, one prior chemotherapy regimen, measurable disease, and a Gynecologic Oncology Group (GOG)...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2008-02, Vol.13 (1), p.62-65 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 65 |
|---|---|
| container_issue | 1 |
| container_start_page | 62 |
| container_title | International journal of clinical oncology |
| container_volume | 13 |
| creator | Homesley, Howard D. Meltzer, Nathan P. Nieves, Lucybeth Vaccarello, Luis Lowendowski, George S. Elbendary, Al A. |
| description | Background
The efficacy of weekly paclitaxel has not been well characterized in either cervical or endometrial cancer.
Methods
Eligible women had disseminated endometrial or squamous cell cancer of the cervix, one prior chemotherapy regimen, measurable disease, and a Gynecologic Oncology Group (GOG) performance status of 0–2. At entry, all laboratory results were within normal limits. Paclitaxel 80 mg/m
2
was administered by intravenous infusion over 1 h every 7 days. Response served as the endpoint of the trial.
Results
Forty-four patients were registered, and 15 of 16 patients with endometrial cancer and 20 of 28 patients with cervical cancer were evaluable for response. Four of the 15 (26.7%) endometrial cancer patients responded to treatment, with one complete response of 22 weeks and three partial responses. Stable disease was present in 26.7%. Two of the 20 (10%) cervical cancer patients responded to treatment, with one complete response of 25 weeks and one partial response of 14 weeks. Stable disease was present in 35%. Adverse effects were minimal and easily managed with dose adjustments as needed.
Conclusion
Although confirmatory larger trials are needed, weekly paclitaxel appears promising for advanced endometrial carcinoma, and possibly for squamous cell carcinoma of the cervix. |
| doi_str_mv | 10.1007/s10147-007-0731-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70351552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70351552</sourcerecordid><originalsourceid>FETCH-LOGICAL-c461t-604ae7bcf4c96ae8cf42d3dcf4686e50c845d3a4715fee41b4afffe471cc693</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAWyQV-wMnsSO02VV8aiExAL2luuM25S8sBOgf4-rVGLHas7Id67kQ8g18DvgXN0H4CAUi8i4SoHJEzIFkSqmlEpOI6cC2DxL5IRchLDjHFQmk3MygTzliicwJZsF7bYmIF2taO9LU9HW0W_Ej2pPgW3bwdPO2KrszQ9W1AQa0LZNwaqyQdpv0ZtuT13rKTZFW-NYYZqCWvRfpY2LNU3kS3LmTBXw6jhn5O3x4X35zF5en1bLxQuzIoOeZVwYVGvrhJ1nBvMISZEWcWR5hpLbXMgiNUKBdIgC1sI45zDu1mbzdEZux9bOt58Dhl7XZbBYVabBdgha8VSClEkMwhi0vg3Bo9OdL2vj9xq4PrjVo1t9wINbLePNzbF8WNdY_F0cZcZAMgZCfGo26PUu-mvid_9p_QX2GYVp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70351552</pqid></control><display><type>article</type><title>A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Homesley, Howard D. ; Meltzer, Nathan P. ; Nieves, Lucybeth ; Vaccarello, Luis ; Lowendowski, George S. ; Elbendary, Al A.</creator><creatorcontrib>Homesley, Howard D. ; Meltzer, Nathan P. ; Nieves, Lucybeth ; Vaccarello, Luis ; Lowendowski, George S. ; Elbendary, Al A.</creatorcontrib><description>Background
The efficacy of weekly paclitaxel has not been well characterized in either cervical or endometrial cancer.
Methods
Eligible women had disseminated endometrial or squamous cell cancer of the cervix, one prior chemotherapy regimen, measurable disease, and a Gynecologic Oncology Group (GOG) performance status of 0–2. At entry, all laboratory results were within normal limits. Paclitaxel 80 mg/m
2
was administered by intravenous infusion over 1 h every 7 days. Response served as the endpoint of the trial.
Results
Forty-four patients were registered, and 15 of 16 patients with endometrial cancer and 20 of 28 patients with cervical cancer were evaluable for response. Four of the 15 (26.7%) endometrial cancer patients responded to treatment, with one complete response of 22 weeks and three partial responses. Stable disease was present in 26.7%. Two of the 20 (10%) cervical cancer patients responded to treatment, with one complete response of 25 weeks and one partial response of 14 weeks. Stable disease was present in 35%. Adverse effects were minimal and easily managed with dose adjustments as needed.
Conclusion
Although confirmatory larger trials are needed, weekly paclitaxel appears promising for advanced endometrial carcinoma, and possibly for squamous cell carcinoma of the cervix.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-007-0731-5</identifier><identifier>PMID: 18307021</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Antineoplastic Agents, Phytogenic - administration & dosage ; Cancer Research ; Carcinoma, Squamous Cell - drug therapy ; Drug Administration Schedule ; Endometrial Neoplasms - drug therapy ; Female ; Humans ; Infusions, Intravenous ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Paclitaxel - administration & dosage ; Surgical Oncology ; Uterine Cervical Neoplasms - drug therapy</subject><ispartof>International journal of clinical oncology, 2008-02, Vol.13 (1), p.62-65</ispartof><rights>Japan Society of Clinical Oncology 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c461t-604ae7bcf4c96ae8cf42d3dcf4686e50c845d3a4715fee41b4afffe471cc693</citedby><cites>FETCH-LOGICAL-c461t-604ae7bcf4c96ae8cf42d3dcf4686e50c845d3a4715fee41b4afffe471cc693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-007-0731-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-007-0731-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18307021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Homesley, Howard D.</creatorcontrib><creatorcontrib>Meltzer, Nathan P.</creatorcontrib><creatorcontrib>Nieves, Lucybeth</creatorcontrib><creatorcontrib>Vaccarello, Luis</creatorcontrib><creatorcontrib>Lowendowski, George S.</creatorcontrib><creatorcontrib>Elbendary, Al A.</creatorcontrib><title>A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
The efficacy of weekly paclitaxel has not been well characterized in either cervical or endometrial cancer.
Methods
Eligible women had disseminated endometrial or squamous cell cancer of the cervix, one prior chemotherapy regimen, measurable disease, and a Gynecologic Oncology Group (GOG) performance status of 0–2. At entry, all laboratory results were within normal limits. Paclitaxel 80 mg/m
2
was administered by intravenous infusion over 1 h every 7 days. Response served as the endpoint of the trial.
Results
Forty-four patients were registered, and 15 of 16 patients with endometrial cancer and 20 of 28 patients with cervical cancer were evaluable for response. Four of the 15 (26.7%) endometrial cancer patients responded to treatment, with one complete response of 22 weeks and three partial responses. Stable disease was present in 26.7%. Two of the 20 (10%) cervical cancer patients responded to treatment, with one complete response of 25 weeks and one partial response of 14 weeks. Stable disease was present in 35%. Adverse effects were minimal and easily managed with dose adjustments as needed.
Conclusion
Although confirmatory larger trials are needed, weekly paclitaxel appears promising for advanced endometrial carcinoma, and possibly for squamous cell carcinoma of the cervix.</description><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Cancer Research</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Drug Administration Schedule</subject><subject>Endometrial Neoplasms - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Paclitaxel - administration & dosage</subject><subject>Surgical Oncology</subject><subject>Uterine Cervical Neoplasms - drug therapy</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwAWyQV-wMnsSO02VV8aiExAL2luuM25S8sBOgf4-rVGLHas7Id67kQ8g18DvgXN0H4CAUi8i4SoHJEzIFkSqmlEpOI6cC2DxL5IRchLDjHFQmk3MygTzliicwJZsF7bYmIF2taO9LU9HW0W_Ej2pPgW3bwdPO2KrszQ9W1AQa0LZNwaqyQdpv0ZtuT13rKTZFW-NYYZqCWvRfpY2LNU3kS3LmTBXw6jhn5O3x4X35zF5en1bLxQuzIoOeZVwYVGvrhJ1nBvMISZEWcWR5hpLbXMgiNUKBdIgC1sI45zDu1mbzdEZux9bOt58Dhl7XZbBYVabBdgha8VSClEkMwhi0vg3Bo9OdL2vj9xq4PrjVo1t9wINbLePNzbF8WNdY_F0cZcZAMgZCfGo26PUu-mvid_9p_QX2GYVp</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Homesley, Howard D.</creator><creator>Meltzer, Nathan P.</creator><creator>Nieves, Lucybeth</creator><creator>Vaccarello, Luis</creator><creator>Lowendowski, George S.</creator><creator>Elbendary, Al A.</creator><general>Springer Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer</title><author>Homesley, Howard D. ; Meltzer, Nathan P. ; Nieves, Lucybeth ; Vaccarello, Luis ; Lowendowski, George S. ; Elbendary, Al A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c461t-604ae7bcf4c96ae8cf42d3dcf4686e50c845d3a4715fee41b4afffe471cc693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Cancer Research</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Drug Administration Schedule</topic><topic>Endometrial Neoplasms - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Paclitaxel - administration & dosage</topic><topic>Surgical Oncology</topic><topic>Uterine Cervical Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Homesley, Howard D.</creatorcontrib><creatorcontrib>Meltzer, Nathan P.</creatorcontrib><creatorcontrib>Nieves, Lucybeth</creatorcontrib><creatorcontrib>Vaccarello, Luis</creatorcontrib><creatorcontrib>Lowendowski, George S.</creatorcontrib><creatorcontrib>Elbendary, Al A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Homesley, Howard D.</au><au>Meltzer, Nathan P.</au><au>Nieves, Lucybeth</au><au>Vaccarello, Luis</au><au>Lowendowski, George S.</au><au>Elbendary, Al A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>13</volume><issue>1</issue><spage>62</spage><epage>65</epage><pages>62-65</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
The efficacy of weekly paclitaxel has not been well characterized in either cervical or endometrial cancer.
Methods
Eligible women had disseminated endometrial or squamous cell cancer of the cervix, one prior chemotherapy regimen, measurable disease, and a Gynecologic Oncology Group (GOG) performance status of 0–2. At entry, all laboratory results were within normal limits. Paclitaxel 80 mg/m
2
was administered by intravenous infusion over 1 h every 7 days. Response served as the endpoint of the trial.
Results
Forty-four patients were registered, and 15 of 16 patients with endometrial cancer and 20 of 28 patients with cervical cancer were evaluable for response. Four of the 15 (26.7%) endometrial cancer patients responded to treatment, with one complete response of 22 weeks and three partial responses. Stable disease was present in 26.7%. Two of the 20 (10%) cervical cancer patients responded to treatment, with one complete response of 25 weeks and one partial response of 14 weeks. Stable disease was present in 35%. Adverse effects were minimal and easily managed with dose adjustments as needed.
Conclusion
Although confirmatory larger trials are needed, weekly paclitaxel appears promising for advanced endometrial carcinoma, and possibly for squamous cell carcinoma of the cervix.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>18307021</pmid><doi>10.1007/s10147-007-0731-5</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2008-02, Vol.13 (1), p.62-65 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70351552 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antineoplastic Agents, Phytogenic - administration & dosage Cancer Research Carcinoma, Squamous Cell - drug therapy Drug Administration Schedule Endometrial Neoplasms - drug therapy Female Humans Infusions, Intravenous Medicine Medicine & Public Health Oncology Original Article Paclitaxel - administration & dosage Surgical Oncology Uterine Cervical Neoplasms - drug therapy |
| title | A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A16%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20trial%20of%20weekly%201-hour%20paclitaxel%20as%20second-line%20therapy%20for%20endometrial%20and%20cervical%20cancer&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Homesley,%20Howard%20D.&rft.date=2008-02-01&rft.volume=13&rft.issue=1&rft.spage=62&rft.epage=65&rft.pages=62-65&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-007-0731-5&rft_dat=%3Cproquest_cross%3E70351552%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70351552&rft_id=info:pmid/18307021&rfr_iscdi=true |